Clinical Trial Update: A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating BI 764198 in adults and adolescents with focal segmental glomerulosclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• BI 764198 (BI-764198)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Focal Segmental Glomerulosclerosis | Phase 3 | Status: RECRUITING